CDH1 and acromegaly: Similar to our findings, several other studies have confirmed the strong role of this marker for acromegaly treatment response and behavior [14,30,37], such as the one by Puig-Domingo et al., where they concluded that E-Cadherin might be the best predictor of biochemical response to fgSRL, independent of SSTR2 or histologic subtypes [30].